Zentiva Pharma Gmbh Pharmaceutical Import Profile — Belgium (DGFT 2022–2026)

Name: Zentiva Pharma Gmbh Pharmaceutical Import Records from India — 2 Products, $19.6M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Zentiva Pharma Gmbh — Pharmaceutical Importer Profile (2026) | 2 Products, $19.6M Trade | TransData Nexus

Zentiva Pharma Gmbh

Pharmaceutical Importer · Belgium · Diabetes & Endocrine Focus · $19.6M Total Trade · DGFT Verified

Zentiva Pharma Gmbh is a pharmaceutical importer based in Belgium with a total trade value of $19.6M across 2 products in 2 therapeutic categories. Based on 520 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Zentiva Pharma Gmbh sources from 3 verified Indian suppliers, with Zentiva Private Limited accounting for 97.4% of imports.

Zentiva Pharma Gmbh — Import Portfolio & Supplier Network

Zentiva Pharma Gmbh import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Zentiva Pharma Gmbh?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Zentiva Private Limited	$46.0M	1,685	97.4%
Intas Pharmaceuticals Limited	$1.1M	30	2.3%
Usv Private Limited	$100.0K

What Formulations Does Zentiva Pharma Gmbh Import?

Formulation	Value	Ships
Pharmaceutical products - metformin	$11.4M	359
Pharmaceutical products - ramilich 5MG	$3.9M	101
Pharmaceutical products - ramilich 2.5MG	$1.4M	47
Pharmaceutical products - clopidogrel	$1.3M	30
Pharmaceutical products - ramilich 10MG	$1.3M	35
Pharmaceutical products - ramilich	$1.2M	49
Pharmaceutical article / ods / product / item - metformin	$992.1K	34
Pharmaceutical products - metformin	$801.3K	22
Pharamaceutical products - metformin licht 1g tabco bl9x20 m36	$417.2K	13
Pharmaceutical article / ods / product / item - ramilich 5MG	$372.3K	9
Pharamaceutical products - ramilich 5mgtab bl5x20 m36	$350.3K	12
Pharma drugs and medi bupropion	$268.2K	8
Pharamaceutical products - ibuflam 800mgtabco bl10x10 m36	$263.1K	8
Pharmaceutical products - ramilich 5MG TAB bl5x20 m36 de (164851 pieces	$219.8K	6
Pharamaceutical products- metformin licht 1g tabco bl9x20 m36	$219.7K	9

Zentiva Pharma Gmbh imports 614 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Metformin	Diabetes & Endocrine	$16.7M	461	3.6%	5
2	Clopidogrel	Cardiovascular	$3.0M	59	1.2%	13

Zentiva Pharma Gmbh imports 2 pharmaceutical products across 2 categories into Belgium totaling $19.6M.

Zentiva Pharma Gmbh — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Zentiva Pharma GmbH is a pharmaceutical importer and buyer based in Belgium, specializing in the acquisition of finished pharmaceutical formulations from India. The company operates as a subsidiary of Zentiva Group, a leading European pharmaceutical manufacturer headquartered in Prague, Czech Republic. Zentiva Group has a rich history spanning over 500 years, with its origins tracing back to a small pharmacy in Prague established in 1488. Over the centuries, Zentiva has evolved into a prominent player in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of high-quality, affordable medicines across Europe.

In 2018, Zentiva was acquired by the private equity firm Advent International, marking a significant milestone in its strategic growth. This acquisition enabled Zentiva to expand its operations and product portfolio, reinforcing its commitment to providing accessible healthcare solutions. The company's Belgian subsidiary, Zentiva Pharma GmbH, plays a crucial role in sourcing and importing pharmaceutical products, particularly from India, to meet the diverse healthcare needs of the Belgian market.

2Distribution Network

Zentiva Pharma GmbH's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products throughout Belgium. While specific warehouse locations are not publicly disclosed, the company leverages Zentiva Group's extensive infrastructure, including manufacturing sites in Prague, Bucharest, and Ankleshwar, India, to facilitate the import and distribution of finished pharmaceutical formulations. This network enables Zentiva Pharma GmbH to maintain a steady supply chain, ensuring timely availability of essential medicines across the country.

The company's logistics capabilities are enhanced by its affiliation with Zentiva Group, which operates a broad network of external manufacturing partners and distribution centers across Europe. This extensive network allows Zentiva Pharma GmbH to effectively manage the importation and distribution of pharmaceutical products, ensuring that they reach healthcare providers and patients in a timely and efficient manner.

3Industry Role

Zentiva Pharma GmbH serves as a key importer and distributor within Belgium's pharmaceutical supply chain. By sourcing finished pharmaceutical formulations from India, the company ensures a consistent supply of essential medicines to the Belgian market. This role is vital in maintaining the availability of affordable and high-quality pharmaceuticals, particularly in therapeutic areas such as diabetes and cardiovascular health. Through its operations, Zentiva Pharma GmbH contributes significantly to the healthcare system by providing a reliable source of generic medicines, thereby supporting the overall well-being of the Belgian population.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Zentiva Pharma Gmbh

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Zentiva Pharma GmbH's sourcing strategy exhibits a high degree of concentration, with a significant majority of its pharmaceutical imports originating from a single supplier, Zentiva Private Limited. In 2022-2026, Zentiva Private Limited accounted for approximately 97.4% of the total import value, amounting to $46.0 million across 1,685 shipments. This substantial reliance indicates a strategic choice to maintain a streamlined and efficient supply chain, leveraging the established relationship with Zentiva Private Limited to ensure consistent product quality and availability.

The limited number of suppliers—three in total—suggests a focused procurement approach. While this concentration can lead to operational efficiencies and stronger supplier relationships, it also introduces potential risks. Any disruptions affecting Zentiva Private Limited could significantly impact Zentiva Pharma GmbH's ability to meet market demand. Therefore, it is essential for the company to assess and manage these risks proactively, possibly by exploring additional supplier partnerships or developing contingency plans to mitigate potential supply chain disruptions.

2Supply Chain Resilience

Zentiva Pharma GmbH's supply chain resilience is closely tied to its sourcing strategy. The company's heavy reliance on Zentiva Private Limited for the majority of its pharmaceutical imports from India means that any disruptions at this supplier could have a substantial impact on Zentiva Pharma GmbH's operations. To enhance supply chain resilience, it would be prudent for the company to diversify its supplier base, thereby reducing dependency on a single source and mitigating potential risks associated with supply chain disruptions.

Importing Pharmaceuticals into Belgium — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Belgium

1Regulatory Authority & Framework

In Belgium, the Federal Agency for Medicines and Health Products (FAMHP) is the primary regulatory authority overseeing the pharmaceutical sector. The FAMHP is responsible for ensuring the safety, efficacy, and quality of medicines available in Belgium, including those imported from non-EU countries like India. Key legislation governing pharmaceutical imports includes the Royal Decree of 14 December 2006, which outlines the conditions for importing medicinal products, and the Law of 25 March 1964, which establishes the framework for the pharmaceutical industry in Belgium.

The marketing authorization pathway for Indian generics involves several steps. Initially, the FAMHP evaluates the submitted dossier, which must include comprehensive data on the product's quality, safety, and efficacy. If the product is deemed acceptable, the FAMHP grants a marketing authorization, allowing the product to be legally marketed and distributed within Belgium. This process ensures that all pharmaceutical products, including those imported from India, meet the stringent standards set by Belgian authorities.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Belgium are stringent. Importers must obtain an import license from the FAMHP, demonstrating compliance with all regulatory standards. Additionally, the Good Manufacturing Practice (GMP) certificates of foreign manufacturers must be recognized by the FAMHP. Certificates from recognized authorities such as the European Medicines Agency (EMA), the World Health Organization (WHO), or the Pharmaceutical Inspection Co-operation Scheme (PIC/S) are typically accepted. Importers must also hold a wholesale distribution authorization, ensuring that they adhere to the necessary standards for the storage and distribution of medicinal products.

Zentiva Pharma Gmbh — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Zentiva Pharma GmbH's focus on importing finished pharmaceutical formulations in the therapeutic areas of diabetes and cardiovascular health aligns with the growing demand for affordable and effective treatments in these sectors. The high import value of metformin and clopidogrel underscores the significant market need for these medications in Belgium. By concentrating on these therapeutic areas, Zentiva Pharma GmbH can leverage its sourcing strategy to meet the specific healthcare needs of the Belgian population, ensuring access to essential medicines.

2Sourcing Profile

Zentiva Pharma GmbH's sourcing strategy emphasizes the procurement of generic drugs, particularly those with established efficacy and safety profiles. The company's preference for finished pharmaceutical formulations allows for quicker market entry and reduces the complexities associated with API sourcing and formulation development. India's robust pharmaceutical manufacturing sector, known for its adherence to international quality standards, makes it a strategic partner for Zentiva Pharma GmbH in fulfilling its procurement needs.

3Market Positioning

Frequently Asked Questions — Zentiva Pharma Gmbh

What products does Zentiva Pharma Gmbh import from India?

Zentiva Pharma Gmbh imports 2 pharmaceutical products across 2 categories. Top imports: Metformin ($16.7M), Clopidogrel ($3.0M).

Who supplies pharmaceuticals to Zentiva Pharma Gmbh from India?

Zentiva Pharma Gmbh sources from 3 verified Indian suppliers. The primary supplier is Zentiva Private Limited (97.4% of imports, $46.0M).

What is Zentiva Pharma Gmbh's total pharmaceutical import value?

Zentiva Pharma Gmbh's total pharmaceutical import value from India is $19.6M, based on 520 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Zentiva Pharma Gmbh focus on?

Zentiva Pharma Gmbh imports across 2 categories. The largest: Diabetes & Endocrine (85.0%), Cardiovascular (15.0%).

Get Full Zentiva Pharma Gmbh Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.